

Listing of Claims

1. – 48. (Cancelled)

49. (Currently amended) A method of expressing delivering a therapeutic or an antigenic protein or peptide in to an individual, the method comprising:

administering to the individual an effective amount of a chimaeric chimeric virus comprising a heterologous nucleic acid sequence encoding the therapeutic or the antigenic protein or peptide wherein the nucleic acid sequence is under control of an expression control sequence, or a pharmaceutical composition thereof, wherein the chimaericchimeric virus is produced by a method comprising culturing a host cell which comprises:

~~one or more~~ Simian Immunodeficiency Virus (SIV) Gag-Pol nucleic acid sequence[[s]] under control of an expression control sequence, wherein said SIV Gag-Pol nucleic acid sequence[[s]] encode[[s]] an SIV capsid,

~~and which further comprises~~ a vector comprising a Human Immunodeficiency Virus type 2 (HIV-2) packaging signal and the heterologous nucleic acid sequence,

SIV accessory genes necessary for viral assembly, and

an envelope coding sequence under control of expression control sequences;

wherein said culturing results in said vector being packaged in the SIV capsid to produce the chimaericchimeric virus.

50. (Previously presented) The method according to claim 49 wherein the individual is a human or non-human primate.